We dig into trust, prices, and a bit of baseball in this week's Health Care Inc. newsletter.

Roche is reviewing all future investments in Germany over health care cost-cutting ​policies, with a top executive citing a ...

China is proposing new restrictions on foreign acquisitions of critical biopharma technologies, as the country seeks to ...

The Republican party’s confusing messaging on vaccines is going to hurt candidates in the midterms, two former GOP congressmen argue.

A STAT investigation found that several nonprofits are raking in massive sums by acting as arbitrators in a program that ...

Isomorphic Labs wants to turn its technology into an engine for new medicines. The question now is whether — and how — it can ...

Internal emails obtained by STAT show that the American Association of Immunologists is sharply divided over California's ...

Silence on vaccines is becoming a dealbreaker for voters who would otherwise vote Republican,” write physicians and former ...

"The hardest years of my life," is how Cambridge scientist David Sabatini describes the time since his downfall from MIT.

Bipartisan legislation under review in Congress has the potential to significantly rejigger global drug development — and the biggest beneficiaries may not be American. The bill, titled the Biotech ...

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...

Changes to the annual performance review process are the latest flashpoint in tensions between federal workers across the ...